By Kyle Morris

Shares in ImmuPharma PLC rose 9.4% on Monday after the company said it has submitted a Phase 2/3 clinical trial protocol to the U.S. Food and Drug Administration for its Lupuzor candidate for Lupus patients.

The company said the new trial design takes into account FDA guidance from a previous meeting, and that the Phase 2/3 study remains on track to commence in the second half.

"We are extremely pleased to be moving positively forward with the Lupuzor(TM) program. Avion and ourselves believe that the new design of the Phase 2/3 adaptive study offers the greatest probability of a successful result for the overall benefit of Lupus patients. We remain on track to commence the trial in H2 2023," Chief Executive Tim McCarthy said.

Shares at 0738 GMT were up 0.17 pence at 2.00 pence.

Write to Kyle Morris at kyle.morris@dowjones.com

(END) Dow Jones Newswires

March 27, 2023 04:08 ET (08:08 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Immupharma (LSE:IMM)
Historical Stock Chart
From Nov 2024 to Dec 2024 Click Here for more Immupharma Charts.
Immupharma (LSE:IMM)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more Immupharma Charts.